Preoperative Radiotherapy Leads to Significant Differences in the Plasma Protein Profile of Rectal Cancer Patients

Introduction: Colorectal cancer (CRC) is the third most common cancer worldwide, accounting for 10% of the global cancer burden. Rectal cancer accounts for around 30% of CRC cases, and patients with resectable rectal cancer are often given preoperative radiotherapy (PRT) to reduce the rate of local...

Full description

Saved in:
Bibliographic Details
Published inOncology Vol. 98; no. 7; pp. 493 - 500
Main Authors Holm, Matilda, Joenväärä, Sakari, Saraswat, Mayank, Tohmola, Tiialotta, Ristimäki, Ari, Renkonen, Risto, Haglund, Caj
Format Journal Article
LanguageEnglish
Published Basel, Switzerland 01.07.2020
Subjects
Clinical Translational Research
Preoperative radiotherapy
Plasma
Mass spectrometry
Colorectal cancer
Proteomics
Online AccessGet full text

Cover

Abstract Introduction: Colorectal cancer (CRC) is the third most common cancer worldwide, accounting for 10% of the global cancer burden. Rectal cancer accounts for around 30% of CRC cases, and patients with resectable rectal cancer are often given preoperative radiotherapy (PRT) to reduce the rate of local recurrence. The human plasma proteome is an exceptionally complex proteome and ideal to study due to its ability to reflect the presence of diseases such as cancer and the ease of obtaining blood samples. Previous proteomic studies involving rectal cancer patients have mostly focused on the identification of proteins involved in resistance to radiotherapy. Objective: The aim of this study was to investigate the overall effects of PRT on plasma protein expression in rectal cancer patients, as there is a lack of such studies. Methods: Here, we have used mass spectrometry and subsequent statistical analyses to analyze the plasma samples of 30 rectal cancer patients according to PRT status (positive or negative) and tumor stage (II or III). Results and Conclusions: We discovered 42 proteins whose levels differed significantly between stage II and III rectal cancer patients who did or did not receive PRT. This study shows that PRT, although localized to the pelvis, leads to measurable, tumor stage-specific changes in plasma protein expression. Future studies of plasma proteins should, when relevant, take this into account and be aware of the widespread effects that PRT has on the plasma proteome.
AbstractList Colorectal cancer (CRC) is the third most common cancer worldwide, accounting for 10% of the global cancer burden. Rectal cancer accounts for around 30% of CRC cases, and patients with resectable rectal cancer are often given preoperative radiotherapy (PRT) to reduce the rate of local recurrence. The human plasma proteome is an exceptionally complex proteome and ideal to study due to its ability to reflect the presence of diseases such as cancer and the ease of obtaining blood samples. Previous proteomic studies involving rectal cancer patients have mostly focused on the identification of proteins involved in resistance to radiotherapy. The aim of this study was to investigate the overall effects of PRT on plasma protein expression in rectal cancer patients, as there is a lack of such studies. Here, we have used mass spectrometry and subsequent statistical analyses to analyze the plasma samples of 30 rectal cancer patients according to PRT status (positive or negative) and tumor stage (II or III). We discovered 42 proteins whose levels differed significantly between stage II and III rectal cancer patients who did or did not receive PRT. This study shows that PRT, although localized to the pelvis, leads to measurable, tumor stage-specific changes in plasma protein expression. Future studies of plasma proteins should, when relevant, take this into account and be aware of the widespread effects that PRT has on the plasma proteome.
Introduction: Colorectal cancer (CRC) is the third most common cancer worldwide, accounting for 10% of the global cancer burden. Rectal cancer accounts for around 30% of CRC cases, and patients with resectable rectal cancer are often given preoperative radiotherapy (PRT) to reduce the rate of local recurrence. The human plasma proteome is an exceptionally complex proteome and ideal to study due to its ability to reflect the presence of diseases such as cancer and the ease of obtaining blood samples. Previous proteomic studies involving rectal cancer patients have mostly focused on the identification of proteins involved in resistance to radiotherapy. Objective: The aim of this study was to investigate the overall effects of PRT on plasma protein expression in rectal cancer patients, as there is a lack of such studies. Methods: Here, we have used mass spectrometry and subsequent statistical analyses to analyze the plasma samples of 30 rectal cancer patients according to PRT status (positive or negative) and tumor stage (II or III). Results and Conclusions: We discovered 42 proteins whose levels differed significantly between stage II and III rectal cancer patients who did or did not receive PRT. This study shows that PRT, although localized to the pelvis, leads to measurable, tumor stage-specific changes in plasma protein expression. Future studies of plasma proteins should, when relevant, take this into account and be aware of the widespread effects that PRT has on the plasma proteome.
Author Tohmola, Tiialotta
Ristimäki, Ari
Holm, Matilda
Saraswat, Mayank
Joenväärä, Sakari
Renkonen, Risto
Haglund, Caj
Author_xml – sequence: 1
  givenname: Matilda
  surname: Holm
  fullname: Holm, Matilda
  email: *Matilda Holm, Departments of Surgery and Pathology, University of Helsinki, Haartmaninkatu 8, FI–00290 Helsinki (Finland), matilda.holm@helsinki.fi
– sequence: 2
  givenname: Sakari
  surname: Joenväärä
  fullname: Joenväärä, Sakari
– sequence: 3
  givenname: Mayank
  surname: Saraswat
  fullname: Saraswat, Mayank
– sequence: 4
  givenname: Tiialotta
  surname: Tohmola
  fullname: Tohmola, Tiialotta
– sequence: 5
  givenname: Ari
  surname: Ristimäki
  fullname: Ristimäki, Ari
– sequence: 6
  givenname: Risto
  surname: Renkonen
  fullname: Renkonen, Risto
– sequence: 7
  givenname: Caj
  surname: Haglund
  fullname: Haglund, Caj
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32294655$$D View this record in MEDLINE/PubMed
BookMark eNpt0EtLxDAQAOAgivvQg3eRgOdq3t0epT6hsGXV85JNJ2u025YkCvvvDVQ9eRpm5mOGmRk67PoOEDqj5IpSWVwTQiSRqsgP0JQKxjPCODtEU0I4yZigYoJmIbwnlkuhjtGEM1YIJeUU-dpDP4DX0X0BXunG9fEtpcMeV6CbgGOPn922c9YZ3UV866wFD52BgF2Hk8V1q8NO49r3EVIpRetawL3FKzBRt7jUiXtcpx3QxXCCjqxuA5z-xDl6vb97KR-zavnwVN5UmZGMxaxpBPCNVYIzbTeSMpBSccXtQhXMgDHA5YJxYRaS5FaLxnClgNCCEpGbnPE5uhjnDp-bHTTrwbud9vv17_EJnI_gQ_st-D8w_jK1L_9tL8tqFOuhsfwbXx1yXQ
CitedBy_id crossref_primary_10_3390_genes13112006
crossref_primary_10_3390_cancers14040993
crossref_primary_10_1016_j_molstruc_2021_132150
crossref_primary_10_1109_TCBB_2021_3068381
crossref_primary_10_3389_fimmu_2022_876195
ContentType Journal Article
Copyright The Author(s). Published by S. Karger AG, Basel
2020 S. Karger AG, Basel.
Copyright_xml – notice: The Author(s). Published by S. Karger AG, Basel
– notice: 2020 S. Karger AG, Basel.
DBID M--
NPM
DOI 10.1159/000505697
DatabaseName Karger Open Access Journals
PubMed
DatabaseTitle PubMed
DatabaseTitleList PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: M--
  name: Karger Open Access Journals
  url: https://www.karger.com/OpenAccess
  sourceTypes:
    Enrichment Source
    Publisher
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1423-0232
EndPage 500
ExternalDocumentID 32294655
505697
Genre Journal Article
GroupedDBID ---
-~X
.GJ
0R~
0~5
0~B
123
29N
30W
328
34G
36B
39C
3O.
3V.
4.4
53G
5RE
7RV
7X7
88E
8AO
8C1
8FI
8FJ
8G5
8UI
AAYIC
ABJNI
ABPAZ
ABUWG
ACGFS
ACPRK
ACPSR
ADAGL
AENEX
AEYAO
AFDXO
AFFNX
AFJJK
AFKRA
AHMBA
ALDHI
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AZPMC
AZQEC
BENPR
BKEYQ
BKNYI
BPHCQ
BVXVI
CAG
CCPQU
COF
CS3
CYUIP
DU5
DWQXO
E0A
EBS
EJD
EMB
EMOBN
EX3
F5P
FB.
FYUFA
GNUQQ
GUQSH
HMCUK
HZ~
IAO
IHR
IHW
IY7
K9-
L7B
M--
M0R
M1P
M2O
N9A
NAPCQ
O1H
O9-
OHT
PQQKQ
PROAC
PSQYO
RIG
RKO
RXVBD
SJN
SV3
UDS
UJ6
UKHRP
WOW
YYQ
ZGI
ZXP
ITC
NPM
ID FETCH-LOGICAL-c522t-dd4e3bf6432afb512e556363f8692cecce358234c8507fa4dc366e0191047c723
IEDL.DBID M--
ISSN 0030-2414
IngestDate Sat Sep 28 08:28:13 EDT 2024
Thu Aug 29 12:04:37 EDT 2024
Thu Sep 05 17:57:51 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 7
Keywords Preoperative radiotherapy
Plasma
Mass spectrometry
Colorectal cancer
Proteomics
Language English
License This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission.
2020 S. Karger AG, Basel.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c522t-dd4e3bf6432afb512e556363f8692cecce358234c8507fa4dc366e0191047c723
OpenAccessLink https://karger.com/doi/10.1159/000505697
PMID 32294655
PageCount 8
ParticipantIDs karger_primary_505697
pubmed_primary_32294655
PublicationCentury 2000
PublicationDate 2020-07-01
PublicationDateYYYYMMDD 2020-07-01
PublicationDate_xml – month: 07
  year: 2020
  text: 2020-07-01
  day: 01
PublicationDecade 2020
PublicationPlace Basel, Switzerland
PublicationPlace_xml – name: Basel, Switzerland
– name: Switzerland
PublicationTitle Oncology
PublicationTitleAlternate Oncology
PublicationYear 2020
References Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.http://dx.doi.org/10.3322/caac.21492
Hanash SM, Pitteri SJ, Faca VM. Mining the plasma proteome for cancer biomarkers. Nature. 2008;452(7187):571–9.
Eriksson D, Stigbrand T. Radiation-induced cell death mechanisms. Tumour Biol. 2010;31(4):363–72.
Chauvin A, Wang CS, Geha S, Garde-Granger P, Mathieu AA, Lacasse V, . The response to neoadjuvant chemoradiotherapy with 5-fluorouracil in locally advanced rectal cancer patients: a predictive proteomic signature. Clin Proteomics. 2018;15:16.
Chang L, Graham P, Hao J, Bucci J, Malouf D, Gillatt D, . Proteomics discovery of radioresistant cancer biomarkers for radiotherapy. Cancer Lett. 2015;369(2):289–97.
Park SY, Lee SJ, Cho HJ, Kim JT, Yoon HR, Lee KH, . Epsilon-globin HBE1 enhances radiotherapy resistance by down-regulating BCL11A in colorectal cancer cells. Cancers (Basel). 2019;11(4).
Tamas K, Walenkamp AM, de Vries EG, van Vugt MA, Beets-Tan RG, van Etten B, . Rectal and colon cancer: not just a different anatomic site. Cancer Treat Rev. 2015;41(8):671–9.
Camma C, Giunta M, Fiorica F, Pagliaro L, Craxi A, Cottone M. Preoperative radiotherapy for resectable rectal cancer: a meta-analysis. JAMA. 2000;284(8):1008–15.
Peng J, Gygi SP. Proteomics: the move to mixtures. J Mass Spectrom. 2001;36(10):1083–91.
Allal AS, Kahne T, Reverdin AK, Lippert H, Schlegel W, Reymond MA. Radioresistance-related proteins in rectal cancer. Proteomics. 2004;4(8):2261–9.
Silva JC, Gorenstein MV, Li GZ, Vissers JP, Geromanos SJ. Absolute quantification of proteins by LCMSE: a virtue of parallel MS acquisition. Mol Cell Proteomics. 2006;5(1):144–56.
Lacombe J, Azria D, Mange A, Solassol J. Proteomic approaches to identify biomarkers predictive of radiotherapy outcomes. Expert Rev Proteomics. 2013;10(1):33–42.
Hvidberg V, Maniecki MB, Jacobsen C, Hojrup P, Moller HJ, Moestrup SK. Identification of the receptor scavenging hemopexin-heme complexes. Blood. 2005;106(7):2572–9.
Anderson NL, Anderson NG. The human plasma proteome. Mol Cell Proteomics. 2002;1(11):845–67.
Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, . Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345(9):638–46.
Folkesson J, Birgisson H, Pahlman L, Cedermark B, Glimelius B, Gunnarsson U. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol. 2005;23(24):5644–50.
Lee RA, Kim HA, Kang BY, Kim KH. Hemoglobin induces colon cancer cell proliferation by release of reactive oxygen species. World J Gastroenterol. 2006;12(35):5644–50.
Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683–91.
Holm M, Saraswat M, Joenvaara S, Ristimaki A, Haglund C, Renkonen R. Colorectal cancer patients with different C-reactive protein levels and 5-year survival times can be differentiated with quantitative serum proteomics. PLoS One. 2018;13(4):e0195354.
Hong TS, Clark JW, Haigis KM. Cancers of the colon and rectum: identical or fraternal twins. Cancer Discov. 2012;2(2):117–21.
Baskar R, Dai J, Wenlong N, Yeo R, Yeoh KW. Biological response of cancer cells to radiation treatment. Front Mol Biosci. 2014;1:24.
Smith FM, Gallagher WM, Fox E, Stephens RB, Rexhepaj E, PetricoinEF, 3rd, . Combination of SELDI-TOF-MS and data mining provides early-stage response prediction for rectal tumors undergoing multimodal neoadjuvant therapy. Ann Surg. 2007;245(2):259–66.
Zheng Y, Miyamoto DT, Wittner BS, Sullivan JP, Aceto N, Jordan NV, . Expression of beta-globin by cancer cells promotes cell survival during blood-borne dissemination. Nat Commun. 2017;8:14344.
Lomax ME, Folkes LK, O’Neill P. Biological consequences of radiation-induced DNA damage: relevance to radiotherapy. Clin Oncol (R Coll Radiol). 2013;25(10):578–85.
Deutsch EW, Csordas A, Sun Z, Jarnuczak A, Perez-Riverol Y, Ternent T, . The ProteomeXchange consortium in 2017: supporting the cultural change in proteomics public data deposition. Nucleic Acids Res. 2017;45(D1):D1100–D6.
Repetto O, De Re V, De Paoli A, Belluco C, Alessandrini L, Canzonieri V, . Identification of protein clusters predictive of tumor response in rectal cancer patients receiving neoadjuvant chemo-radiotherapy. Oncotarget. 2017;8(17):28328–41.
Bowden DL, Sutton PA, Wall MA, Jithesh PV, Jenkins RE, Palmer DH, . Proteomic profiling of rectal cancer reveals acid ceramidase is implicated in radiation response. J Proteomics. 2018;179:53–60.
References_xml
SSID ssj0007546
Score 2.356794
Snippet Introduction: Colorectal cancer (CRC) is the third most common cancer worldwide, accounting for 10% of the global cancer burden. Rectal cancer accounts for...
Colorectal cancer (CRC) is the third most common cancer worldwide, accounting for 10% of the global cancer burden. Rectal cancer accounts for around 30% of CRC...
SourceID pubmed
karger
SourceType Index Database
Enrichment Source
Publisher
StartPage 493
SubjectTerms Clinical Translational Research
Title Preoperative Radiotherapy Leads to Significant Differences in the Plasma Protein Profile of Rectal Cancer Patients
URI https://karger.com/doi/10.1159/000505697
https://www.ncbi.nlm.nih.gov/pubmed/32294655
Volume 98
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1LS8NAEB60QulFfFStVtmD14V2s3kdpVqK2BrUQm9lsw8pYlLSePDfO5tdCxa85LCbB8y3yfclmfkG4JYNNNMDE9JQ8IDynIVUKCOoHqTKJFwlyiXIzqLJnD8uwoX_3mFrYT5s_nNjjbr1FkDCbVrPIVWn8T4csDiKbPLWlNLtMzf2JTm4ZClyEvceQn8O7UAbV29qDcOQbtyFdsRkQyrjIzj0apDcOfiOYU8XJ9Ce-v_dp1BllS7X2rlzkxehVr5g6pvY3pgbUpfkdfVe2HwfDBG59-1O8OYnq4LgviRDefwpSGb9GHAocz26SWkIKkZU3mRkca9I5gxWN12Yjx_eRhPquyRQidqppkpxHeQGlQUTJkf-1tbzKwpMEqVMIkLaFsMGXCYo_YzgSgZRpFHZWZMGGbPgDFpFWegLIEOm-JDJPE605FKHObI3j1MtlVIo_FQPui5sy7Wzwli6yPagvzP-PHpyU8u1Mj04d0HeTv_icPnPCa-gw-x7bZMW24dWXX3payT_Or9pcMftLJv-AMuqqdE
link.rule.ids 315,786,790,27668,27957,27958
linkProvider Karger AG
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Preoperative+Radiotherapy+Leads+to+Significant+Differences+in+the+Plasma+Protein+Profile+of+Rectal+Cancer+Patients&rft.jtitle=Oncology&rft.au=Holm%2C+Matilda&rft.au=Joenv%C3%A4%C3%A4r%C3%A4%2C+Sakari&rft.au=Saraswat%2C+Mayank&rft.au=Tohmola%2C+Tiialotta&rft.date=2020-07-01&rft.issn=0030-2414&rft.eissn=1423-0232&rft.volume=98&rft.issue=7&rft.spage=493&rft.epage=500&rft_id=info:doi/10.1159%2F000505697&rft_id=info%3Apmid%2F32294655&rft.externalDocID=505697
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0030-2414&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0030-2414&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0030-2414&client=summon